CD47 is overexpressed in various types of cancers and it can directly bind with SIRPα, which is mainly located on macrophages. The binding of CD47-SIRPα transmits a “don't eat me” signal, which can prevent cancer cells from immune clearance. Targeting the phagocytosis checkpoint of CD47-SIRPα axis has shown remarkable anticancer effect in preclinical and clinical research, which indicates the potential application of CD47-SIRPα blockade for cancer treatment. In this case, the comprehensive description of the regulation of CD47 in different types of cancer cells has significant implications for furthering our understanding of the role of CD47 in cancer. Based on the current reports, we summarized the regulatory factors, i.e., cytokines, oncogenes, microRNAs as well as enzymes, of CD47 expression in cancer cells. Accordingly, we also proposed several points needing further research, hoping to provide useful insights for the future investigation on the regulation of CD47 in cancers.

CD47在各种类型的癌症中过度表达，并且可以直接与SIRPα结合，而SIRPα主要位于巨噬细胞上。CD47-SIRPα的结合传递了一个“不要吃我”的信号，可以阻止癌细胞的免疫清除。针对CD47-SIRPα轴的吞噬作用检查点，在临床前和临床研究中显示出显着的抗癌作用，这表明CD47-SIRPα阻断剂在癌症治疗中具有潜在的应用前景。在这种情况下，对CD47在不同类型的癌细胞中的调控的全面描述对于进一步理解CD47在癌症中的作用具有重要意义。根据当前的报告，我们总结了监管因素，即，CD47在癌细胞中的表达，细胞因子，致癌基因，微小RNA以及酶。因此，我们还提出了一些需要进一步研究的观点，希望为癌症CD47调控的未来研究提供有用的见解。